Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

A possible sale could fund Entolimod development, while retaining production rights remains a priority for Valion.

Rhea-AI Summary

Valion Bio (NASDAQ:VBIO) has received unsolicited acquisition inquiries from independent third parties for its wholly owned manufacturing subsidiary, Velocity Bioworks.

Valion has entered preliminary discussions and is evaluating strategic options, including a possible sale, while continuing to operate Velocity and pursue new customers. It has retained an investment banking firm to advise its board on a potential transaction. The review will consider valuation, terms, execution certainty and potential net proceeds.

Valion identifies retaining production rights and securing continued manufacturing capabilities for Entolimod, and potentially other pipeline assets, as a priority. Depending on its structure, a sale could provide capital for Entolimod development and other corporate priorities. Discussions remain preliminary, with no commitment to a sale or other specific transaction.

3 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointUnsolicited acquisition inquiries from independent third parties open a possible sale path for Velocity.
• Minor point. Forward-looking: it has not happened yet and may not happen.A potential sale could provide additional development capital, depending on its structure.
• Minor pointVelocity commercial development continues as Valion pursues new customer relationships alongside transaction discussions.

Negative

• Moderate pointDiscussions remain preliminary; Valion has not committed to a sale or any specific transaction.

Argus 15 min delay 29 alerts

-6.38% vs previous close $0.88 last price 811.1x rel. volume Open Argus

Details

Market move: VBIO -6.38% vs previous close. unsolicited acquisition interest

+13.6% Peak in 0 min

$0.77 – $1.38 Day Range

$1.90M Mkt Cap at Last Price

On Oct 26, the day this news came out, the latest delayed price for VBIO is 6.38% below the previous close. Argus tracked a peak move of +13.6% during the session. Our momentum scanner has recorded 29 alerts for this stock so far that day. The latest delayed price is $0.88. Relative volume is exceptionally heavy at 811.1x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Historical Context

1 past event · Latest: Oct 21

1 event

1. Oct 21

   strategic review

   24h Move

   -5.9%

   Outlined strategic options for Velocity, including a potential sale, without committing to a transaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cdmo, animal rule, toll-like receptor 5 agonist, nf-κb

4 terms

cdmo technical

"wholly owned contract development and manufacturing organization ("CDMO")"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

animal rule regulatory

"evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule"

A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.

toll-like receptor 5 agonist medical

"a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways"

A toll-like receptor 5 (TLR5) agonist is a drug or molecule that binds to and activates TLR5, a protein on certain immune cells that senses bacterial flagellin and triggers innate immune responses. Think of TLR5 as a doorbell on immune cells and an agonist as the button that rings it, prompting inflammation or immune activation; investors care because this mechanism is used in vaccines and cancer or infectious‑disease therapies and affects clinical effects, safety, and regulatory review.

nf-κb medical

"activate NF-κB signaling pathways associated with cellular protection"

NF-κB is a protein complex inside cells that acts like a master switch for inflammation, immune responses and cell survival; when turned on it tells many genes to produce signals that promote immune activity, cell growth or protection from stress. Investors care because drugs or diagnostics that affect NF-κB can influence treatments for cancers, autoimmune disorders and inflammatory diseases, so changes in NF-κB activity can meaningfully alter a therapy’s potential market and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that it has received unsolicited acquisition inquiries from independent third parties concerning its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks ("Velocity"). The Company has entered into preliminary discussions with these interested parties while continuing to evaluate a range of strategic options for Velocity.

These discussions are consistent with the strategic priorities outlined in Valion's October 21, 2026 announcement, including advancing its lead biologic drug candidate, Entolimod, and other pipeline assets, building Velocity's commercial business, and evaluating strategic opportunities for the CDMO subsidiary.

"Our strategic review is focused on determining how best to maximize the potential of each asset," said Dean Zikria, Interim Chief Executive Officer of Valion. "The unsolicited interest in Velocity provides an opportunity to evaluate a range of strategic options, including a possible sale. Our priority remains identifying the path that best supports our development objectives and delivers long-term value to shareholders."

Velocity provides U.S.-based biologics development and manufacturing capabilities that support Valion's internal pipeline and are available to biotechnology companies advancing early-phase programs. Alongside these discussions, Valion continues to operate the subsidiary and pursue new customer relationships.

Valion has retained a nationally recognized investment banking firm to serve as financial advisor to its Board of Directors ("Board") in evaluating a potential transaction. Management and the Board will consider the proposed valuation and terms, execution certainty, and potential net proceeds. In evaluating any potential transaction, a key priority for Valion will be retaining production rights and securing continued manufacturing capabilities for Entolimod and potentially other assets in the Company's development pipeline. Depending on its structure, a sale could provide additional capital for Entolimod's ongoing development and other corporate priorities while positioning Velocity for growth under new ownership.

Discussions remain preliminary, and Valion has not committed to a sale or any other specific transaction. There can be no assurance that these discussions will lead to a definitive agreement or a completed transaction on acceptable terms, or at all. The Company continues to evaluate the full range of strategic opportunities for Velocity and does not expect to provide further updates unless a definitive agreement is reached, or the Board determines that disclosure is appropriate or legally required.

About Valion Bio, Inc.

Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.

The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome ("ARS") and has been evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced neutropenia, and other indications.

Valion is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company's pipeline includes potential programs in neutropenia and immune dysfunction.

Valion's wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.

For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements in this press release include, among others, statements regarding: the timing and success of preclinical and clinical trials and study results, including the AFRRI/NIAID studies described herein; the development and regulatory advancement of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions; the initiation, design, timing and outcome of investigator-sponsored studies in neutropenia; the potential sale of Velocity; the development and potential applications of Entolasta; the ability of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company's ability to obtain additional capital and the continued listing of the Company's common stock on the Nasdaq Capital Market. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Valion's actual results to differ from those contained in the forward-looking statements, see Valion's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as required by applicable law.

Investor and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com

SOURCE: Valion Bio, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Is Valion Bio selling Velocity Bioworks?

Valion is evaluating a possible sale after receiving unsolicited acquisition inquiries, but has not committed to a transaction. Discussions with independent third parties remain preliminary.

What manufacturing arrangements would Valion prioritize in a Velocity transaction?

Valion identifies retaining production rights and securing continued manufacturing capabilities for Entolimod as a priority in evaluating a potential transaction. That priority could also extend to other assets in its development pipeline.

When will Valion Bio update shareholders on the Velocity discussions?

Valion does not expect to provide further updates unless a definitive agreement is reached or its board determines disclosure is appropriate or legally required.